ScreenerHero

NTHI NeOnc Technologies Holdings, Inc.

NAS · US · Healthcare · Biotechnology · neonc.com
2.710USD-9.36%Mkt Cap: 78.06M $P/E: —

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap78.06M USD
Enterprise Value75.81M USD
Revenue (TTM)39.99K USD
Gross Profit39.99K USD
Net Income (TTM)-62.15M USD
Revenue/Share0.0020 USD
Last Price2.710 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.74
PEG—
EV/EBITDA—
EV/Revenue1895.74
P/S2153.74
P/B-3.43
EPS (TTM)-2.16
EPS (Forward)-1.09
52W Range
2.6501% of range12.99
52W High12.99 USD
52W Low2.650 USD
Profitability
Gross Margin100.00%
Oper. Margin-104418.90%
EBITDA Margin0.00%
Profit Margin-155404.38%
ROE354.96%
ROA-2200.93%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.36M USD
CapEx (TTM)500.00K USD
FCF Margin13506.62%
FCF Yield6.92%
Net Debt-1.65M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.36
Current Ratio0.18
Quick Ratio0.09
Book Value/Sh-0.87 USD
Cash/Share0.08 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.00 USD
Upside (mean)+527.3%
Target Range13.00 USD – 20.00 USD
13.00+527.3% to mean20.00
# Analysts4
Ownership
Shares Out.28.81M
Float8.10M
Insiders49.77%
Institutions10.98%
Short Interest
Short Ratio2.5d
Short % Float3.81%
Short % Out.1.81%
Shares Short522.31K
Short (prev mo.)597.82K
Technical
SMA 503.856 (-29.7%)
SMA 2006.019 (-55.0%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)191.74K
Avg Vol (10d)159.43K
Technical Indicators
RSI (14)35.0
MACD-0.3016
MACD Signal-0.2702
MACD Hist.-0.0313
BB Upper3.802 USD
BB Middle3.262 USD
BB Lower2.721 USD
BB Width33.14%
ATR (14)0.3642 USD
Vol Ratio (20d)1.11x